NASDAQ:ELUT Elutia (ELUT) Stock Price, News & Analysis → The key to this new pathway to wealth is literally a key (From Porter & Company) (Ad) Free ELUT Stock Alerts $4.96 +0.72 (+16.98%) (As of 06/28/2024 ET) Add Compare Share Share Today's Range$4.31▼$4.9950-Day Range$2.77▼$4.9652-Week Range$1.10▼$4.99Volume222,263 shsAverage Volume97,627 shsMarket Capitalization$120.38 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Elutia alerts: Email Address Elutia MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside111.7% Upside$10.50 Price TargetShort InterestHealthy0.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 starsMedical Sector452nd out of 919 stocksBiological Products, Except Diagnostic Industry67th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingElutia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageElutia has only been the subject of 2 research reports in the past 90 days.Read more about Elutia's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.05% of the float of Elutia has been sold short.Short Interest Ratio / Days to CoverElutia has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elutia has recently decreased by 1.37%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldElutia does not currently pay a dividend.Dividend GrowthElutia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELUT. Previous Next 2.1 News and Social Media Coverage News SentimentElutia has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Elutia this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Elutia to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elutia insiders have not sold or bought any company stock.Percentage Held by Insiders40.80% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Elutia's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Elutia is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elutia is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Elutia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. About Elutia Stock (NASDAQ:ELUT)Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Read More ELUT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELUT Stock News HeadlinesJune 24, 2024 | americanbankingnews.comElutia Inc. to Post FY2024 Earnings of ($1.37) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:ELUT)June 23, 2024 | americanbankingnews.comLake Street Capital Increases Elutia (NASDAQ:ELUT) Price Target to $10.00June 29, 2024 | The Freeport Society (Ad)Odds of Biden Replacement Up 105%!The media has now officially turned on him. But while Trump supporters are celebrating… The Democratic party is readying a Plan B that could change the face of America forever.June 23, 2024 | americanbankingnews.comHead-To-Head Contrast: Elutia (NASDAQ:ELUT) & Fennec Pharmaceuticals (NASDAQ:FENC)June 19, 2024 | americanbankingnews.comElutia (NASDAQ:ELUT) Price Target Raised to $11.00June 17, 2024 | globenewswire.comElutia Announces $13.26 Million Registered Direct OfferingJune 17, 2024 | globenewswire.comElutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and DefibrillatorsMay 13, 2024 | finance.yahoo.comElutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024June 29, 2024 | The Freeport Society (Ad)Odds of Biden Replacement Up 105%!The media has now officially turned on him. But while Trump supporters are celebrating… The Democratic party is readying a Plan B that could change the face of America forever.May 10, 2024 | investorplace.comELUT Stock Earnings: Elutia Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comElutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA ClearanceMay 2, 2024 | finance.yahoo.comElutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024April 24, 2024 | globenewswire.comElutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1March 10, 2024 | finanznachrichten.deElutia Inc.: Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM Clearance Decision in First Half of 2024March 10, 2024 | finance.yahoo.comElutia Full Year 2023 Earnings: Misses ExpectationsMarch 8, 2024 | finance.yahoo.comQ4 2023 Elutia Inc Earnings CallMarch 7, 2024 | investorplace.comELUT Stock Earnings: Elutia Misses EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Elutia Q4 EarningsMarch 7, 2024 | globenewswire.comElutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024March 6, 2024 | benzinga.comPreview: Elutia's EarningsFebruary 22, 2024 | globenewswire.comElutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024February 22, 2024 | finance.yahoo.comUmoja Biopharma to Participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech ConferenceFebruary 21, 2024 | finance.yahoo.comCalliditas Year-end report, January - December 2023February 11, 2024 | wsj.comElutia Inc.February 9, 2024 | proactiveinvestors.comElutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical ImplantsFebruary 4, 2024 | msn.comAziyo Biologics Announces Executive Compensation AdjustmentsJanuary 11, 2024 | finanznachrichten.deElutia Inc.: Elutia Regains Compliance with Nasdaq Listing RequirementsSee More Headlines Receive ELUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elutia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/29/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ELUT CUSIPN/A CIK1708527 Webwww.elutia.com Phone240-247-1170Fax510-307-9896Employees54Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$11.00 Low Stock Price Target$10.00 Potential Upside/Downside+111.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,660,000.00 Net Margins-164.45% Pretax Margin-170.52% Return on EquityN/A Return on Assets-112.77% Debt Debt-to-Equity RatioN/A Current Ratio0.63 Quick Ratio0.55 Sales & Book Value Annual Sales$24.75 million Price / Sales4.86 Cash FlowN/A Price / Cash FlowN/A Book Value($1.66) per share Price / Book-2.99Miscellaneous Outstanding Shares24,270,000Free Float14,370,000Market Cap$120.38 million OptionableNot Optionable Beta0.61 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. C. Randal Mills Ph.D. (Age 52)Co-Founder, President & CEO and Director Comp: $857.26kMr. Matthew B. Ferguson (Age 56)Chief Financial Officer Comp: $360.65kMs. Erica ElchinVice President of Global OperationsDr. Michelle LeRoux Williams Ph.D. (Age 49)Chief Scientific Officer Ms. Courtney GuyerVice President of MarketingDr. Sonali Fonseca Ph.D.VP & Head of Emerging BusinessesMr. Jeffry D. HametSenior VP of Finance, Treasurer & SecretaryMore ExecutivesKey CompetitorsAlectorNASDAQ:ALECVoyager TherapeuticsNASDAQ:VYGRTaysha Gene TherapiesNASDAQ:TSHAOcugenNASDAQ:OCGNEditas MedicineNASDAQ:EDITView All CompetitorsInstitutional OwnershipPerkins Capital Management Inc.Bought 797,602 shares on 5/10/2024Ownership: 3.286%Verdence Capital Advisors LLCBought 14,410 shares on 4/26/2024Ownership: 0.059%View All Institutional Transactions ELUT Stock Analysis - Frequently Asked Questions Should I buy or sell Elutia stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elutia in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELUT shares. View ELUT analyst ratings or view top-rated stocks. What is Elutia's stock price target for 2024? 2 equities research analysts have issued 1 year price objectives for Elutia's stock. Their ELUT share price targets range from $10.00 to $11.00. On average, they expect the company's share price to reach $10.50 in the next year. This suggests a possible upside of 111.7% from the stock's current price. View analysts price targets for ELUT or view top-rated stocks among Wall Street analysts. How have ELUT shares performed in 2024? Elutia's stock was trading at $2.16 at the beginning of the year. Since then, ELUT stock has increased by 129.6% and is now trading at $4.96. View the best growth stocks for 2024 here. When is Elutia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ELUT earnings forecast. How were Elutia's earnings last quarter? Elutia Inc. (NASDAQ:ELUT) issued its earnings results on Thursday, May, 9th. The company reported ($0.75) earnings per share for the quarter. The firm earned $6.69 million during the quarter. Who are Elutia's major shareholders? Elutia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (3.29%) and Verdence Capital Advisors LLC (0.06%). Insiders that own company stock include Birchview Capital, Lp, Brigid Makes, David Colpman, Highcape Capital, LP, Matthew Ferguson and Thomas Englese. View institutional ownership trends. How do I buy shares of Elutia? Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELUT) was last updated on 6/29/2024 by MarketBeat.com Staff From Our PartnersJoe Biden Facing Political “Knockout” In Weeks?Joe Biden Facing Political “Knockout” In Weeks? Weeks from now, we are expecting Joe Biden to make a histor...Banyan Hill Publishing | SponsoredBiden’s inner circle turns against him?On August 19, the Democratic party will take the stage in Chicago and officially nominate their presidential c...Paradigm Press | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
